{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:22:37Z","timestamp":1790648557444,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T00:00:00Z","timestamp":1614643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Blood eosinophil count may predict treatment response in patients with chronic obstructive pulmonary disease (COPD) during acute exacerbations (AE). However, the ability and thresholds of blood eosinophil counts in stable status to predict eosinophilic AECOPD have not been completely investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective multicenter study performed January 2010 to December 2014. COPD subjects hospitalized with exacerbations, were included. Blood samples were obtained at the time of AE and stable disease at outpatient clinic before or after admission. We identified a blood eosinophil count cut-off point at stable COPD, either taken as a percentage or as absolute value, for identification of eosinophilic exacerbation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was significant positive correlation of eosinophil counts between stable COPD and AECOPD. The best cut-off value of blood eosinophil count in stable status for the prediction of eosinophilic COPD exacerbation based on blood eosinophil count\u2009\u2265\u20092% was 300 cells\/\u00b5L (area under the ROC curve [AUC] 0.614,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001, 39% sensitivity, 83.8% specificity). When the eosinophilic COPD exacerbation was based on blood eosinophil count\u2009\u2265\u2009300 cells\/\u00b5L, the best cut-off value of blood eosinophil count in stable status for the prediction of eosinophilic COPD exacerbation was also 300 cells\/uL (AUC 0.634,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.046, 45.8% sensitivity, 80.9% specificity).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We demonstrated association between blood eosinophil counts at stable COPD and those with AECOPD. The thresholds of blood counts at stable COPD to predict eosinophilic exacerbations was 300 cells\/\u00b5L. Further and prospective studies in other populations should validate our results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-021-01443-4","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T07:05:28Z","timestamp":1614668728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The association between eosinophilic exacerbation and eosinophilic levels in stable COPD"],"prefix":"10.1186","volume":"21","author":[{"given":"Hye Seon","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Haak","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Kyu","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4533-7937","authenticated-orcid":false,"given":"Chin Kook","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,2]]},"reference":[{"issue":"6","key":"1443_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1164\/rccm.201104-0597OC","volume":"184","author":"M Bafadhel","year":"2011","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184(6):662\u201371.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1443_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1164\/rccm.201108-1553OC","volume":"186","author":"M Bafadhel","year":"2012","unstructured":"Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48\u201355.","journal-title":"Am J Respir Crit Care Med"},{"key":"1443_CR3","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.2147\/COPD.S100338","volume":"11","author":"NA Negewo","year":"2016","unstructured":"Negewo NA, McDonald VM, Baines KJ, Wark PA, Simpson JL, Jones PW, Gibson PG. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:1495\u2013504.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1443_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.chest.2019.02.406","volume":"156","author":"MI MacDonald","year":"2019","unstructured":"MacDonald MI, Osadnik CR, Bulfin L, Hamza K, Leong P, Wong A, King PT, Bardin PG. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. Chest. 2019;156(1):92\u2013100.","journal-title":"Chest"},{"key":"1443_CR5","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2147\/COPD.S37611","volume":"7","author":"AM Alaithan","year":"2012","unstructured":"Alaithan AM, Memon JI, Rehmani RS, Qureshi AA, Salam A. Chronic obstructive pulmonary disease: hospital and intensive care unit outcomes in the Kingdom of Saudi Arabia. Int J Chron Obstruct Pulmon Dis. 2012;7:819\u201323.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1443_CR6","first-page":"283","volume":"7","author":"Y Kitaguchi","year":"2012","unstructured":"Kitaguchi Y, Komatsu Y, Fujimoto K, Hanaoka M, Kubo K. Sputum eosinophilia can predict responsiveness to inhaled corticosteroid treatment in patients with overlap syndrome of COPD and asthma. Int J Chron Obstruct Pulmon Dis. 2012;7:283\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1443_CR7","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.2147\/COPD.S116072","volume":"11","author":"HS Kang","year":"2016","unstructured":"Kang HS, Rhee CK, Kim SK, Kim JW, Lee SH, Yoon HK, Ahn JH, Kim YH. Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2467\u201373.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1443_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pupt.2016.03.004","volume":"37","author":"L Serafino-Agrusa","year":"2016","unstructured":"Serafino-Agrusa L, Scichilone N, Spatafora M, Battaglia S. Blood eosinophils and treatment response in hospitalized exacerbations of chronic obstructive pulmonary disease: a case-control study. Pulm Pharmacol Ther. 2016;37:89\u201394.","journal-title":"Pulm Pharmacol Ther"},{"issue":"3","key":"1443_CR9","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.chest.2019.04.012","volume":"156","author":"DM Schumann","year":"2019","unstructured":"Schumann DM, Tamm M, Kostikas K, Stolz D. Stability of the blood eosinophilic phenotype in stable and exacerbated COPD. Chest. 2019;156(3):456\u201365.","journal-title":"Chest"},{"issue":"4","key":"1443_CR10","doi-asserted-by":"publisher","first-page":"1700853","DOI":"10.1183\/13993003.00853-2017","volume":"50","author":"VL Kim","year":"2017","unstructured":"Kim VL, Coombs NA, Staples KJ, Ostridge KK, Williams NP, Wootton SA, Devaster JM, Aris E, Clarke SC, Tuck AC, et al. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017;50(4):1700853.","journal-title":"Eur Respir J"},{"issue":"2","key":"1443_CR11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1183\/13993003.00419-2015","volume":"46","author":"CJ Ryerson","year":"2015","unstructured":"Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015;46(2):512\u201320.","journal-title":"Eur Respir J"},{"issue":"4","key":"1443_CR12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/resp.12724","volume":"21","author":"K Hasegawa","year":"2016","unstructured":"Hasegawa K, Camargo CA Jr. Prevalence of blood eosinophilia in hospitalized patients with acute exacerbation of COPD. Respirology. 2016;21(4):761\u20134.","journal-title":"Respirology"},{"issue":"2","key":"1443_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.chest.2016.01.026","volume":"150","author":"M Bafadhel","year":"2016","unstructured":"Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, Hussain SF, Pavord ID, Singh SJ, Steiner MC. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest. 2016;150(2):320\u20138.","journal-title":"Chest"},{"issue":"5","key":"1443_CR14","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S2213-2600(16)00100-4","volume":"4","author":"H Watz","year":"2016","unstructured":"Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390\u20138.","journal-title":"Lancet Respir Med"},{"key":"1443_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2147\/COPD.S189585","volume":"14","author":"J Vestbo","year":"2019","unstructured":"Vestbo J, Vogelmeier CF, Small M, Siddall J, Fogel R, Kostikas K. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population. Int J Chron Obstruct Pulmon Dis. 2019;14:853\u201361.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"1443_CR16","doi-asserted-by":"publisher","first-page":"1700761","DOI":"10.1183\/13993003.00761-2017","volume":"50","author":"M Kerkhof","year":"2017","unstructured":"Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agusti A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E, et al. Blood eosinophil count and exacerbation risk in patients with COPD. Eur Respir J. 2017;50(1):1700761.","journal-title":"Eur Respir J"},{"issue":"6","key":"1443_CR17","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.jaci.2018.04.010","volume":"141","author":"JH Yun","year":"2018","unstructured":"Yun JH, Lamb A, Chase R, Singh D, Parker MM, Saferali A, Vestbo J, Tal-Singer R, Castaldi PJ, Silverman EK, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037-2047.e2010.","journal-title":"J Allergy Clin Immunol"},{"key":"1443_CR18","doi-asserted-by":"crossref","unstructured":"Casanova C, Celli BR, de-Torres JP, Martinez-Gonzalez C, Cosio BG, Pinto-Plata V, de Lucas-Ramos P, Divo M, Fuster A, Peces-Barba G et al: Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J 2017, 50(5).","DOI":"10.1183\/13993003.01162-2017"},{"issue":"4","key":"1443_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","volume":"192","author":"SH Siddiqui","year":"2015","unstructured":"Siddiqui SH, Guasconi A, Vestbo J, Jones P, Agusti A, Paggiaro P, Wedzicha JA, Singh D. Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523\u20135.","journal-title":"Am J Respir Crit Care Med"},{"key":"1443_CR20","unstructured":"2020 GOLD REPORTS."},{"key":"1443_CR21","doi-asserted-by":"crossref","unstructured":"Schumann DM, Tamm M, Kostikas K, Stolz D: Stability of the blood eosinophilic phenotype in stable and exacerbated COPD. Chest 2019.","DOI":"10.1183\/13993003.congress-2018.PA5477"},{"issue":"6","key":"1443_CR22","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1183\/09031936.00162414","volume":"44","author":"D Singh","year":"2014","unstructured":"Singh D, Kolsum U, Brightling CE, Locantore N, Agusti A, Tal-Singer R. Investigators E: Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697\u2013700.","journal-title":"Eur Respir J"},{"issue":"5","key":"1443_CR23","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1183\/13993003.01370-2015","volume":"47","author":"NC Barnes","year":"2016","unstructured":"Barnes NC, Sharma R, Lettis S, Calverley PM. Blood eosinophils as a marker of response to inhaled corticosteroids in COPD. Eur Respir J. 2016;47(5):1374\u201382.","journal-title":"Eur Respir J"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12890-021-01443-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-021-01443-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T07:11:42Z","timestamp":1614669102000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-021-01443-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1186\/s12890-021-01443-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-25609\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,2]]},"assertion":[{"value":"25 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Clinical Research Ethics Committee of the Catholic Medical Center (IRB No. XC16RIMI0030). The requirement for informed consent was waived by the boards because the study was based on retrospective chart reviews.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CK Rhee received consulting\/lecture fees from MSD, AstraZeneca, GSK, Novartis, Takeda, Mundipharma, Boehringer-Ingelheim, Teva, and Bayer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}